Mumbai, Feb. 13 -- Profit before tax in Q3 FY25 stood at Rs 163.7 crore, down 36.13% as against Rs 256.3 crore reported in the same period a year ago.

The company's revenue from active pharmaceutical ingredient (API) stood at Rs 66.6 crore (up 43.84% YoY), income from domestic formulations was at Rs 96.1 crore (down 3.32% YoY), and revenue from crop health sciences (CHS) came in at Rs 15.1 crore (up 7.09% YoY) during the period under review.

On the other hand, revenue from export formulations slipped 52.81% YoY to Rs 285.8 crore during the quarter.

Meanwhile, the company's board declared a second interim dividend of Rs 1.50 per equity share in FY25. The record date for the same is fixed for Tuesday, 18 February 2025. The payment of the...